Engineering Terpene Synthases for Increased Productivity
工程萜烯合成以提高生产率
基本信息
- 批准号:7113465
- 负责人:
- 金额:$ 4.04万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2006
- 资助国家:美国
- 起止时间:2006-05-01 至 2007-04-13
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION (provided by applicant): Terpenes are the most diverse class of natural products, with 30,000 known members. A number of characterized terpenes form commercially useful products, including the anticancer agent Taxol. Large- scale production of terpenes is difficult because current techniques rely on complex chemical synthesis or inefficient extraction from biological sources. To address the demand for therapeutic terpenes the Keasling laboratory has engineered Escherichia coli to produce amorpha-4,11-diene, the precursor for the anti- malarial compound, artemisinin. However, adequate expression of the terpene synthase, amorphadiene synthase (ADS), has become a major obstacle to increased amorphadiene production. Terpene synthases catalyze the cyclization of polyprenyl diphosphates to form a terpene backbone, which is the first committed step in all terpene biosynthesis. In this proposal, we outline an approach to improve terpene synthase expression in E. coli by increasing both solubility and activity,of the model terpene synthase, ADS, as well as to optimize flux through this enzyme to increase amorphadiene production. Altered ADS enzymes will be analyzed and a model linking terpene synthase sequence to enzyme function will be established.
描述(由申请人提供):萜烯是最多样化的天然产物类别,已知有30,000种成员。许多具有特征的萜烯形成商业上有用的产品,包括抗癌剂紫杉醇。萜烯的大规模生产是困难的,因为目前的技术依赖于复杂的化学合成或从生物来源的低效提取。为了满足对治疗性萜烯的需求,Keasling实验室对大肠杆菌进行了改造,使其产生紫穗槐-4,11-二烯,这是抗疟疾化合物青蒿素的前体。然而,萜烯合酶紫穗槐二烯合酶(ADS)的充分表达已成为紫穗槐二烯产量增加的主要障碍。萜烯脱氢酶催化聚异戊二烯二磷酸环化形成萜烯骨架,这是所有萜烯生物合成中的第一个关键步骤。在这个建议中,我们概述了一种方法,以提高萜烯合酶表达在大肠杆菌。通过增加模型萜烯合酶ADS的溶解度和活性,以及优化通过该酶的通量以增加紫穗槐二烯的产量,来提高大肠杆菌的产量。将分析改变的ADS酶,并建立将萜烯合酶序列与酶功能联系起来的模型。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jennifer Rachel Anthony其他文献
Jennifer Rachel Anthony的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似海外基金
Serotonin N-Acetyl-Transferase Inhibitors for Circadian Rhythm Disorders
血清素 N-乙酰转移酶抑制剂治疗昼夜节律紊乱
- 批准号:
10522741 - 财政年份:2022
- 资助金额:
$ 4.04万 - 项目类别:
Chemoprotection & Immune Remodeling after Hematopoietic Progenitor Cell Gene Therapy for Glioblastoma
化学保护
- 批准号:
10470774 - 财政年份:2019
- 资助金额:
$ 4.04万 - 项目类别:
O6-Alkylguanine-DNA Alkyltransferase Repair of Modified Pyrimidines
O6-烷基鸟嘌呤-DNA 烷基转移酶修复修饰的嘧啶
- 批准号:
498189-2016 - 财政年份:2016
- 资助金额:
$ 4.04万 - 项目类别:
University Undergraduate Student Research Awards
Chemistry and Mechanism of Direct DNA Repair Proteins
DNA直接修复蛋白的化学和机制
- 批准号:
7911190 - 财政年份:2009
- 资助金额:
$ 4.04万 - 项目类别:
PHASE I STUDY OF CLORETAZINE(TM) (VNP40101M) IN CHILDREN WITH RECURRENT, PROG
氯雷他嗪 (TM) (VNP40101M) 在复发性、进展性儿童中的 I 期研究
- 批准号:
7605886 - 财政年份:2007
- 资助金额:
$ 4.04万 - 项目类别:
TUMOR SELECTIVE INACTIVATION OF THE REPAIR PROTEIN AGT
修复蛋白 AGT 的肿瘤选择性失活
- 批准号:
7318303 - 财政年份:2007
- 资助金额:
$ 4.04万 - 项目类别:
Studies in the Synthesis of Physiologically Important
生理重要物质的合成研究
- 批准号:
7362069 - 财政年份:2007
- 资助金额:
$ 4.04万 - 项目类别:
Chemoprevention with mTOR & Farnesyltransferase Inhibitors
mTOR 化学预防
- 批准号:
7048765 - 财政年份:2006
- 资助金额:
$ 4.04万 - 项目类别:
Lamin A Mutation and Hutchinson-Gilford Progeria
核纤层蛋白 A 突变和 Hutchinson-Gilford 早衰症
- 批准号:
7104070 - 财政年份:2006
- 资助金额:
$ 4.04万 - 项目类别: